Novartis figure parmi les leaders mondiaux dans le secteur pharmaceutique. 
- produits pharmaceutiques  : maladies cardio-vasculaires, dysfonctionnements du système nerveux central, dermatologie, oncologie, maladies respiratoires, dysfonctionnements hormonaux, etc. Novartis possède par ailleurs près de 50 molécules en phases d'études cliniques
- médicaments génériques )
- para-pharmacie (: produits nutritionnels , produits OTC et autres 
- ophtalmologie . Ciba Vision est le n° 2 mondial des lentilles de contact. Le groupe commercialise également des solutions de nettoyage pour lentilles (20% du CA de la branche)
-santé animale
http://www.novartis.fr

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines
Acquisition of EBEWE Pharma provides strong platform for future growth of differentiated generics business
New global center of excellence for injectable cancer medicines broadens portfolio of affordable medicines for patients
Sandoz to focus on quick and seamless integration for customers and employees
Holzkirchen, September 24, 2009 - Sandoz announced today that it has completed its USD 1.3 billion acquisition of EBEWE Pharma's specialty generic injectables business, paving the way for the creation of a global center of excellence in generic oncology injectables.
"We are delighted to combine EBEWE Pharma's portfolio and pipeline of high-quality injectables with our global leadership in biopharmaceuticals, anti-infectives and other innovative technologies," said Sandoz CEO Jeff George. "This will greatly enhance the range of affordable generic anti-cancer medicines Sandoz offers to patients worldwide."
In addition to globalizing Austrian-based EBEWE's operations through its integration within Sandoz, the world's second largest generics company, the transaction offers Sandoz a complementary portfolio of differentiated generics, with more than 15 marketed products and a strong pipeline with several near-term launches. 
Sandoz and EBEWE Pharma will now focus on implementing their joint integration plans to deliver a smooth transition for all stakeholders. A new global business unit and center of excellence is being created to improve customer service worldwide. The new unit will be based in Unterach, Austria and led by former EBEWE Pharma CEO Friedrich Hillebrand, who will join the Sandoz Executive Committee. 
Key priorities for the integration include capitalizing on EBEWE Pharma's deep hospital marketing capabilities, strong customer partnerships, skills in developing differentiated generics, and expertise in injectables manufacturing. The majority of integration activities are expected to be completed shortly.
Annual sales of the global generic injectables sector were USD 10-12 billion in 2008, according to IMS Health, with injectable oncology medicines accounting for about 30%. Additionally, injectable oncology medicines with a total of USD 9 billion in annual sales are expected to lose patent protection by 2015.

08.04.2009 Coartem® receives FDA approval becoming first artemisinin-based combination treatment (ACT) for malaria in the US

Sandoz receives FDA approval for Omnitrope® Pen 10 with liquid cartridge
New 10mg strength offers increased treatment flexibility and more convenient dosage form 
Comparable quality, safety and efficacy combined with significant cost savings 
Approval further demonstrates Sandoz leadership in high quality follow-on biologics 
New 10mg strength offers increased treatment flexibility and more convenient dosage form
Comparable quality, safety and efficacy combined with significant cost savings 
Approval further demonstrates Sandoz leadership in high quality follow-on biologics
Princeton, New Jersey, September 3, 2008  --  Sandoz has received US Food and Drug Administration approval for its Omnitrope® Pen 10 with liquid cartridge. Omnitrope, a somatropin, is approved for long-term treatment of pediatric patients who have growth failure and long-term replacement therapy in adults with growth hormone deficiency. 
There are approximately 50,000 pediatric patients and 25,000 adult patients who use a somatropin in the US.[1] The Omnitrope Pen 10 with liquid cartridge provides increased treatment flexibility for physicians and a more convenient dosage form for patients. It will also offer significant cost savings compared to the reference product, Genotropin®, and other leading recombinant growth hormones.
"The FDA approval of the 10 mg strength of Omnitrope will allow physicians to treat a broader spectrum of patients with a high quality, lower cost treatment option," said Bernhard Hampl, chief executive officer of Sandoz Inc., the US subsidiary of Sandoz. "Follow-on biologics are a key part of the Sandoz strategy and we are committed to increasing patient access through follow-on biologics once patents have expired."
The 10 mg version has been marketed by Sandoz in key European countries since earlier this year. A 5 mg strength version, Omnitrope Pen 5 with liquid cartridge, has been available in the US since March. 
Omnitrope is highly similar to Genotropin in its safety and efficacy profiles.[2]
Sandoz pioneered the field of follow-on biologics with the approvals and subsequent launches of a lyophilized powder form of Omnitrope in the US and Europe. Omnitrope was the first follow-on biologic to receive approval and be made available to patients in both regions. It was the first ever medicine to be approved in the EU as a biosimilar, the European regulatory term for such products.
Follow-on biologics are a key part of the Sandoz strategy to focus on difficult-to-make generics that provide added patient benefits. Due to the rising costs of health care and the growing need for more complex treatments, they will play an increasingly important role in ensuring access to medicines. Sandoz is building a strong global pipeline of follow-on biologics, with 25 projects currently under development. 

Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Tasigna produced responses in 40% of patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to prior treatment
Approval and availability in US means Novartis can offer physicians and patients a comprehensive treatment approach for this disease
Basel, October 29, 2007 - Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec® (imatinib)*, an established treatment standard and a leading Novartis medicine.
Novartis will make Tasigna available throughout the US within days following this approval by the Food and Drug Administration (FDA) to meet the treatment needs of these patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). 
CML is one of the four most common types of leukemia, a form of blood cancer, and affects around 4,500 people in the US each year[1].
"Tasigna represents an important advance for the small number of patients who are resistant or intolerant to prior therapy," said David Epstein, President and CEO of Novartis Oncology. "This approval means we can offer physicians a comprehensive treatment approach with effective medicines to treat their Ph+ CML patients."
Taken twice daily, Tasigna works by inhibiting the proliferation of cells containing an abnormal chromosome. It does this by targeting the production of the Bcr-Abl protein, which is produced only by cells containing the abnormal Philadelphia chromosome. This protein is recognized as the key cause and driver of the overproduction of cancer-causing white blood cells in patients with Ph+ CML.
Tasigna was specifically designed to target the Bcr-Abl protein more preferentially than Glivec without adding new mechanisms of action. At six months follow-up, Tasigna reduced or eliminated cells carrying the abnormal Philadelphia chromosome in 40% of patients in chronic phase of the disease. 
Applying experience gained from the development of Glivec, which remains the most frequently prescribed treatment for patients with CML, a team of Novartis scientists created Tasigna in August 2002, just a year after the launch of Glivec. In preclinical studies, the medicine was able to overcome resistance resulting from Bcr-Abl kinase mutations in 32 of 33 cell lines commonly associated with Ph+ CML. Patients with a variety of these mutations also responded to treatment with Tasigna.

Novartis announces the retirement of Urs Baerlocher
Urs Baerlocher, a member of the Executive Committee of Novartis since 1999, retires as of August 31 
Basel, August 29, 2007 - Novartis announced today the retirement of Dr. Urs Baerlocher, who was a member of the Executive Committee of Novartis and most recently Head of Legal and Tax Affairs. He will retire at the end of August at the age of 65.
Dr. Thomas Werlen, 42, General Counsel of Novartis since January 2006 will now directly report to Dr. Daniel Vasella, Chairman and Chief Executive Officer of Novartis. He previously reported to Urs Baerlocher. Barbara Kessler, Head of Group Tax and Insurance will report to Dr. Raymund Breu, Group CFO.
"I want to thank Urs Baerlocher for his contributions in overseeing several strong global functions for Novartis. He built a solid legal and tax function, and his skills were particularly helpful in several of our strategic initiatives. Following our signing of the UN Global Compact, Urs Baerlocher advanced our implementation of Novartis' strong Code of Conduct," said Dr. Daniel Vasella, Chairman and CEO of Novartis. 
After working as a tax attorney in Solothurn, Urs Baerlocher joined Sandoz in 1973 and held positions of increasing responsibility, including CEO of the Sandoz Nutrition division and CEO of Sandoz Pharma while also serving on the Sandoz Executive Board. At Novartis, he was named a member of the Executive Committee in 1999. 
Prior to joining Novartis, Dr. Thomas Werlen was a partner in the London office of the international law firm Allen & Overy LLP. He also worked at other law firms in Switzerland and the US. He has a Ph.D in law from the University of Zurich and earned a master's degree  from Harvard Law School. He is a member of the New York and the Swiss bar

17/07/07 Novartis delivers strong performance in first half of 2007 (H1 - Report)
Group first-half net sales advance 14% (+11% in local currencies) to USD 19.9 billion on solid contributions from all divisions
Net income up 14% to USD 4.2 billion and EPS rises 14% to USD 1.78 per share 
Operating income from continuing operations up 13% and net income from continuing operations advances 17% 
New pharmaceutical brands - particularly Tekturna, Lucentis, Exjade and Exforge - performing dynamically; seven major regulatory approvals achieved to date in 2007 
Proceeds from non-core divestments to fund targeted acquisitions and repurchase of up to approximately USD 4 billion of Novartis shares by February 2008 
Outlook maintained for record 2007 operating and net income for continuing operations; Group net sales growth revised to mid-single-digits in local currencies 
Pharmaceuticals net sales growth expected to slow in second half of 2007, mainly from US generic competition for Lotrel and Lamisil and the Zelnorm suspension

Key Group figures First half
H1 2007 H1 2006 % Change   USD m % of 
net sales USD m % of 
net sales USD lc 
Net sales  19 941   17 483   14 11 
Operating income  4 669 23.4 4 262 24.4 10
Net income 4 187 21.0 3 669 21.0 14 
Basic earnings per share/ADS  USD
1.78   USD
1.56   14 
Second quarter
   Q2 2007 Q2 2006 % Change   USD m % of 
net sales USD m % of 
net sales USD lc 
Net sales  10 122   9 182   10 7 
Operating income  2 216 21.9 2 060 22.4 8 
Net income 2 016 19.9 1 713 18.7 18 
Basic earnings per share/ADS  USD
0.86   USD
0.73   18

Basel, July 17, 2007 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: "All areas of our strategic healthcare portfolio performed well in the first half of 2007 despite some setbacks in the Pharmaceuticals Division. Continuing our focus on innovation, we have already achieved seven major regulatory approvals this year and more are expected in the second half. Many of these new products are meeting high expectations, while our leading brands Diovan and Gleevec/Glivec keep growing dynamically. Sandoz and Vaccines and Diagnostics again delivered strong growth. Our complementary healthcare businesses are positioning us well to fulfill a broad spectrum of patient needs and meet the challenges of an increasingly volatile sector."

First half 2007
Net sales    H1 2007 H1 2006      % Change    USD m USD m USD lc 
Pharmaceuticals 11 988 10 751 12 9 
Vaccines and Diagnostics 482 127 
Sandoz 3 415 2 881 19 13 
Consumer Health continuing operations 2 643 2 415  9 6 
Net sales from continuing operations 18 528 16 174 15 11 
Consumer Health discontinuing operations(1) 1 413 1 309 8 7 
Total 19 941 17 483 14 11
(1) Discontinuing operations include Medical Nutrition and Gerber in 2007 and Medical Nutrition, Gerber and Nutrition & Santé in 2006. The divestiture of Medical Nutrition was completed on July 1, 2007.

Group net sales rise 14% (+11% lc) to USD 19.9 billion
Dynamic performances from Sandoz and Vaccines and Diagnostics as well as solid growth in Pharmaceuticals and Consumer Health supported the double-digit expansion. Higher sales volumes represented seven percentage points of growth and acquisitions three percentage points, while currency translation had a positive impact of three points and net price changes added one point. 
Pharmaceuticals net sales advance 12% (+9% lc) to USD 12.0 billion
Ongoing strong growth in the top-selling brands Diovan (USD 2.4 billion, +19% lc) and Gleevec/Glivec (USD 1.4 billion, +14% lc) - both No. 1 in their segments - underpinned the performance. Recently launched brands such as Exforge, Exjade, Lucentis, Prexige and Tekturna/Rasilez continued growing rapidly. US net sales rose 5%, as growth in several brands helped offset the impact of the Zelnorm suspension in March and generic competition for Lotrel starting in May. 
Vaccines and Diagnostics net sales of USD 482 million
Key drivers were growth in deliveries of components for use in combination pediatric vaccines as well as vaccines for tick-borne encephalitis. Diagnostics products, mainly used for blood testing, delivered further double-digit growth. The year-ago period included net sales for only two months following the April 2006 acquisition. Net sales on a comparable basis were up 45% over the 2006 period recorded by Chiron.
Sandoz net sales expand 19% (+13% lc) to USD 3.4 billion
Recent US product launches, in particular for difficult-to-make products, underpinned the dynamic performance as this region accounted for 28% of total net sales. Improving positions in markets such as Eastern Europe, Scandinavia, Canada and Latin America further supported double-digit growth.
Consumer Health continuing operations net sales up 9% (+6% lc) to USD 2.6 billion
OTC provided strong growth ahead of the market thanks to strategic brands and expansion in emerging markets, while Animal Health benefited from further expansion in key markets.

18/10/05 Novartis enregistre une croissance soutenue au cours des neuf premiers mois de 2005 et est en bonne voie pour atteindre ses objectifs annuels de chiffre d’affaires et de bénéfices
20/09/05 Novartis presents positive Phase III data on key compounds and highlights strong late-stage development pipeline 
14/07/05 Novartis enregistre des résultats en forte progression au premier semestre 2005
21/04/05 Novartis continue de devancer le marché avec un chiffre d'affaires et un taux de croissance très soutenus au premier trimestre 2005
Novartis affiche des résultats records avec une croissance à deux chiffres de son chiffre d’affaires net et de son résultat pour 2004